RedHill Biopharma (RDHL) Finished Goods (2017 - 2024)

RedHill Biopharma (RDHL) has 8 years of Finished Goods data on file, last reported at $2.8 million in Q4 2024.

• Finished Goods for Q4 2024 came in at $2.8 million, down 14.96% year-over-year; the trailing twelve-month figure through Dec 2024 was $2.8 million (down 14.96% YoY), and the FY2024 annual result was $2.8 million, down 14.96% from the prior year.
• Finished Goods slipped to $2.8 million in Q4 2024 per RDHL's latest filing, from $3.3 million in the prior quarter.
• Over five years, Finished Goods peaked at $6.8 million in Q4 2022 and troughed at $2.8 million in Q4 2024.
• A 5-year average of $4.9 million and a median of $4.7 million in 2020 frame the typical range for Finished Goods.
• The sharpest annual moves came in 2020 and 2023: Finished Goods soared 1521.23% in 2020, then plunged 51.25% in 2023.
• A 5-year view of Finished Goods shows it stood at $4.7 million in 2020, then soared by 39.48% to $6.6 million in 2021, then gained by 3.39% to $6.8 million in 2022, then sank by 51.25% to $3.3 million in 2023, then retreated by 14.96% to $2.8 million in 2024.
• Business Quant data shows RDHL's Finished Goods at $2.8 million in Q4 2024, $3.3 million in Q4 2023, and $6.8 million in Q4 2022.